Overview

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether prostate cancer growth can be slowed in patients who receive Androgel® 1% at 10 gram dose.
Phase:
Phase 2
Details
Lead Sponsor:
University of Chicago
Collaborator:
Solvay Pharmaceuticals
Treatments:
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate